The company name & ASX ticker
Why our analysts believe it has significant upside
The FDA pathway with key dates
Detailed valuation model & analyst target price
Download the full research report
Includes the company’s name, ASX ticker, full financial model and the analyst’s target price.
By clicking ‘Download Report’, I accept the Privacy Policy and Member Terms & Conditions.
INSIDE THE REPORT
A High-Potential ASX MedTech Opportunity Entering a Major Catalyst Window
This company has built what could become the world's first objective autism test, delivered through an ordinary smartphone in around 15 minutes. No clinic visit. No specialist required.
Their pilot study has already exceeded FDA performance targets. Now the pivotal validation study is underway across 10 leading US autism centres, with an FDA submission targeted by year-end 2026.
A commissioned research house raised its fair value estimate by 37% after pilot results, and values the company at a multiple of today's share price.*
Discover the investment case behind the stock
Backed By Independent Evidence
Peer-reviewed science and a pivotal study run by a global CRO across ten leading US autism centres.
Selected For A Government Rollout
Chosen for a government-funded
nationwide autism screening program overseas.
A Dated FDA Pathway
A late-2026 submission target puts its next major catalyst firmly in sight.
Download the Report
FREE
ACCESS
Important information
General advice only. This page contains general information and is not personal financial advice. It does not take into account your objectives, financial situation or needs. Consider seeking advice from a licensed professional before making any investment decision.
Paid research coverage. The research figures cited on this page were produced by a research house that was engaged and paid by the featured company for ongoing research coverage. Directors or associates of that research house may hold or trade the company’s securities. Valuation figures are a third party’s opinion, may change without notice, and are not a guarantee of future performance.
Forward-looking statements. This page contains forward-looking statements, including anticipated regulatory milestones and market estimates. Such statements are predictions, subject to risks and uncertainties, and actual results may differ materially. All securities involve risk, including adverse or unanticipated market, financial or political developments.
Regulatory status. The featured company is pre-revenue and its lead product is not yet FDA-cleared. Regulatory clearance is not guaranteed. Past performance and forecasts are not reliable indicators of future results.
© East Coast Research. All rights reserved.